Jennifer Lanzer, MD
Urogynecology and Reconstructive Pelvic Surgery · Gainesville, GANPI 1205152154
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $9,783 of the $16,070 with a category attached, or 60.9%. 26 manufacturers reported payments, led by Medtronic at 42.3% of the total. Reporting peaked in 2019 at $4,632 and has fallen 86.0% since, to $650 in 2025.
Across 432 payments — averaging $37.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$7K
- Boston Scientific$2K
- Axonics, Inc.$2K
- Intuitive Surgical$2K
- AbbVie$1K
- Astellas Pharma US Inc$1K
- plus $1K from 20 others
What the payments were for
- Travel & lodging$4,64529%
- Food & beverage$9,78361%
- Education$1,64210%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 134 | $6,804 |
| Boston Scientific | 29 | $2,141 |
| Axonics, Inc. | 79 | $1,795 |
| Intuitive Surgical | 4 | $1,743 |
| AbbVie(2 entities) | 59 | $1,191 |
| Astellas Pharma US Inc | 55 | $1,041 |
| Coloplast | 19 | $384 |
| Pfizer | 24 | $381 |
| Sumitomo Pharma America, Inc. | 4 | $93 |
| Aroa Biosurgery Incorporated | 1 | $77 |
| Coopersurgical, Inc. | 3 | $65 |
| Smith+Nephew | 3 | $57 |
| Baxter Healthcare | 3 | $56 |
| Urovant Sciences Inc | 2 | $34 |
| Vertex | 1 | $33 |
| Johnson & Johnson | 1 | $21 |
| Therapeuticsmd, Inc. | 1 | $20 |
| Millicent US Inc | 1 | $18 |
| Mayne Pharma Commercial LLC | 2 | $17 |
| Bayer | 1 | $15 |
| Avadel Specialty Pharmaceuticals, LLC | 1 | $15 |
| Currax Pharmaceuticals LLC | 1 | $15 |
| Sage Therapeutics, LLC | 1 | $14 |
| Laborie Medical Technologies Corp. | 1 | $14 |
| Hologic Sales And Service, LLC | 1 | $13 |
| Molnlycke Health Care US, LLC | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INTERSTIM$4,146
- DAVINCI XI$1,500
- GENERAL FEMALE SUI$917
- BOTOX$336
- Axonics$252
- Da Vinci Surgical System$220
- Bulkamid$149
- VASCULAR$143
- MYRBETRIQ$125
- Axonics r-SNM System$122
- SOLYX$110
- Solyx SIS System$106
How this compares
$16,070 in reported general payments places this provider in the 80th percentile of 32 urogynecology and reconstructive pelvic surgery providers in Georgia.
See all urogynecology and reconstructive pelvic surgery providers in Georgia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 76 | $37,942 |
| GemtesaVibegron | 18 | $14,794 |
| LinzessLinaclotide | 11 | $5,879 |
| Estradiol | 92 | $5,598 |
| Trospium Chloride | 18 | $774 |
| Cephalexin | 23 | $562 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 22 | $361 |
| Ondansetron OdtOndansetron | 28 | $154 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 37 | $116 |
| Ibuprofen | 27 | $85 |
| Oxycodone Hcl | 28 | $49 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $1,041 | $37,94276 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $93 | $14,79418 claims |
| AbbVieLinzess | $1,191 | $5,87911 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 32 urogynecology and reconstructive pelvic surgery providers in Georgia.
Other urogynecology and reconstructive pelvic surgery in Gainesville
- Jason BaileyGainesville$369K
- Sana AnsariGainesville$3K
- Cheau WilliamsMoultrie$192K
- David LovejoyMacon$85K
- Anne WiskindAtlanta$51K
- Barbara HenleyAugusta$37K
- Ivrose JosephAugusta$17K
- Joseph StubbsSavannah$13K
- Danielle TaylorAugusta$10K
- Joye LowmanAtlanta$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.